SBIO ETF — ALPS Medical Breakthroughs ETF

ALPS Medical Breakthroughs ETF (SBIO)

Updated October 16, 2026.

SBIO is an ETF. its expense ratio is 0.50%. Total return is 119.2% over the past 11.8 years, 231.5 points behind SPY at 350.7%.

ALPS Medical Breakthroughs ETF is a passive index-tracking fund that invests at least eighty percent of its assets in small and mid-cap biotechnology companies with drugs in Phase II or Phase III of FDA clinical trials. The fund does not currently distribute income to shareholders; a special distribution was paid recently but may not recur. The expense ratio is 0.50%, and this fund appeals to investors seeking exposure to clinical-stage biotech companies with development-stage drug candidates.

SBIO performance versus SPY

Price and return data through 2026-10-16.

Total return is 119.2% over the past 11.8 years, 231.5 points behind SPY at 350.7%. Over the past year its total return — price change plus distributions reinvested — is 18.7%. Its deepest 1-year drawdown was 29.2%.

SBIO key facts

Issuer

ALPS

Asset type

ETF

Asset class

Equity

Inception date

12/30/2014

Expense ratio

0.50%

Distribution frequency

None

Last close

$50.12 (as of 2026-10-16)

AUM

$179,200,563

Average volume

20687.0

Ex-dividend date

12/19/2024

Payment date

12/26/2024

Beta

0.92

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: ALPS; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SBIO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 29.2%.

Who may consider SBIO — and who may not

It is a weaker fit for investors who need monthly cash flow (SBIO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SBIO

• All tickers starting with S

Frequently asked questions

More securities from ALPS.